Stocktoria

Werewolf Therapeutics, Inc. HOWL

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-04-30

Werewolf Therapeutics, Inc. statistics & valuation

Market cap$15.7M
P / B0.6×
Net cash$25.0M
Enterprise value USD-$9.3M
Return on capital-182.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
202020212022202320242025
Return on equity (%)
-32.70% -44.00% -33.60% -96.10% -245.20% 202020212022202320242025
Shares outstanding
1.2M 27.3M 31.4M 39.1M 44.8M 48.6M 202020212022202320242025
Net debt ($)
-$94.3M -$78.9M -$25.0M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-15.60% -27.90% -33.60% -21.40% -55.60% -87.60% 202020212022202320242025
Free cash flow margin (%)
202020212022202320242025
Debt / equity (×)
0.36× 0.44× 1.29× 202020212022202320242025
EPS ($)
-$28.08 -$10.94 -$1.86 -$1.05 -$1.63 -$1.33 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Return on assets-87.6%-55.6%-21.4%-33.6%-27.9%-15.6%
Return on equity-245.2%-96.1%-33.6%-44.0%-32.7%29.0%
Debt / equity1.29×0.44×0.36×———
Current ratio1.627.457.145.8413.5617.58

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.